Product Candidate
Discovery
PRECLIN
PHASE 1
PHASE 2
PHASE 3
Launch
Status
HCVProtease inhibitor
glecaprevir-containing combo* (MAVYRET™)
Pan-genotypic: Marketed by AbbVie
HCVProtease inhibitor
paritaprevir-containing regimens
GT1 and GT4: Marketed by AbbVie
NASH & PBCFXR Agonist
EDP-305
Phase 1 Complete
RSVN-protein inhibitor
EDP-938
Preclinical
HVBCore inhibitor
Preclinical
NASHFXR Agonist follow-on
Preclinical
NASHUndisclosed
Discovery

*Fixed-dose combination, formerly known as G/P, contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir

Click here for a printable version (PDF)